GSEP
BIIB icon

Golden State Equity Partners’s Biogen BIIB Stock Holding History

Golden State Equity Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70
Closed -$12.8K – 478
2026
Q1 		$12.8K Buy
+70
New +$12.9K ﹤0.01% 1224
2024
Q4 		– Sell
-9
Closed -$1.74K – 491
2024
Q3 		$1.74K Buy
+9
New +$1.88K ﹤0.01% 813

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Golden State Equity Partners's BIIB Position: Q2 2026 in Review

Golden State Equity Partners sold out of Biogen (BIIB) in Q2 2026, closing a stake of 70 shares — an estimated $12.8K sold.

Golden State Equity Partners first reported a position in BIIB in Q3 2024 and held it in 2 quarters. The position peaked at $12.8K in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Golden State Equity Partners reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 70 Biogen shares in Q2 2026, an estimated $12.8K.
  • Golden State Equity Partners first reported a position in Biogen in Q3 2024 and held it in 2 quarters.
  • Golden State Equity Partners's Biogen position peaked at $12.8K in Q1 2026.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.